Cancer Stem Cell Capture & Characterization

About Counterpoint Biomedica

Counterpoint Biomedica is a private, preclinical-stage biotech firm developing advanced tumor-targeting platforms designed to retrofit existing FDA-approved oncology drugs, improving their precision, efficacy, and safety profile. The company leverages a foundational technology known as Pathotropic (XC-Targeting), which homes in on exposed collagen signatures in tumors, a platform historically validated in clinical gene therapy trials. With an extensive pipeline focused on combination therapies and diagnostics, Counterpoint aims to reduce clinical development costs and timelines for improved cancer treatments while recently securing new patents for targeted pharmaceuticals, cancer stem cell capture, and immunotherapy.

Therapeutic Areas

Other Diagnostics Drugs